Fundz
Real-time · AI · Cross-signal

Abilita Therapeutics and Finnish Orion Corporation just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Abilita Therapeutics and Finnish Orion Corporation, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
Watch the 2-minute tour · with sound

Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in Oncology and Pain Areas

Dec 18, 2024over 1 year ago

Contract Type

partnership

San DiegoBiotechnologyTherapeutics

Description

Abilita Therapeutics, Inc. and Finnish Orion Corporation have entered into a collaboration to leverage Abilita's pioneering EMP™ antibody discovery platform for challenging multi-span membrane protein (MMP) targets, with a focus on oncology and pain. Orion has an option to license an undisclosed Abilita discovery program and select two additional MMP targets for drug discovery over the collaboration period. Abilita has the potential to earn up to $785 million plus royalties on commercial sales

Company Information

Company

Abilita Therapeutics and Finnish Orion Corporation

Location

San Diego, California, United States

About

Abilita Therapeutics, Inc. and Finnish Orion Corporation have announced a global licensing and multi-target research collaboration focused on the discovery, development, and commercialization of next-generation antibody therapeutics in the areas of oncology and pain.

Predictive Intelligence
Strategic

ML-powered predictions for Abilita Therapeutics and Finnish Orion Corporation's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months